Follow
Deepankar Chakroborty
Title
Cited by
Cited by
Year
Transcriptional repressor HIC1 contributes to suppressive function of human induced regulatory T cells
U Ullah, SBA Andrabi, SK Tripathi, O Dirasantha, K Kanduri, S Rautio, ...
Cell reports 22 (8), 2094-2106, 2018
442018
The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotency
MR Emani, E Närvä, A Stubb, D Chakroborty, M Viitala, A Rokka, ...
Stem cell reports 4 (3), 519-528, 2015
342015
An unbiased in vitro screen for activating epidermal growth factor receptor mutations
D Chakroborty, KJ Kurppa, I Paatero, VK Ojala, M Koivu, MZ Tamirat, ...
Journal of Biological Chemistry 294 (24), 9377-9389, 2019
222019
Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target
J Heliste, A Jokilammi, I Paatero, D Chakroborty, C Stark, T Savunen, ...
BMC Cardiovascular Disorders 18, 1-12, 2018
132018
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
E Narvi, K Vaparanta, A Karrila, D Chakroborty, S Knuutila, A Pulliainen, ...
Scientific Reports 8 (1), 16579, 2018
132018
L1TD1 - a prognostic marker for colon cancer
D Chakroborty, MR Emani, R Klén, C Böckelman, J Hagström, C Haglund, ...
BMC cancer 19, 1-9, 2019
112019
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
MKA Koivu, D Chakroborty, MZ Tamirat, MS Johnson, KJ Kurppa, ...
Molecular cancer therapeutics 20 (3), 564-576, 2021
42021
An unbiased functional genetics screen identifies rare activating ERBB4 mutations
D Chakroborty, VK Ojala, AM Knittle, J Drexler, MZ Tamirat, R Ruzicka, ...
Cancer Research Communications 2 (1), 10-27, 2022
32022
Trans-activating mutations of the pseudokinase ERBB3
K Elenius, M Koivu, D Chakroborty, T Airenne, M Johnson, K Kurppa
2023
Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis
M Momeny, M Tienhaara, D Chakroborty, M Sharma, R Varjus, ...
bioRxiv, 2023.06. 14.544493, 2023
2023
Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers
D Chakroborty, I Paatero, KJ Kurppa, K Elenius
bioRxiv, 2022.11. 21.517363, 2022
2022
1685P Oncogenic activity of recurrent ERBB4 mutations and their sensitivity to neratinib
VK Ojala, A Tuohisto-Kokko, S Ahonen, A Jokilammi, OE Gonzalez, ...
Annals of Oncology 33, S1312, 2022
2022
An unbiased in vitro screen for activating ERBB4 mutations
D Chakroborty, VK Ojala, AM Knittle, KJ Kurppa, K Elenius
Cancer Research 82 (12_Supplement), 153-153, 2022
2022
Screen for actionable ERBB3 mutations
MK Koivu, D Chakroborty, KJ Kurppa, K Elenius
Cancer Research 82 (12_Supplement), 828-828, 2022
2022
L1td1 as predictive biomarker of colon cancer
D Chakroborty, EM Reddy, ELO Laura, R Lahesmaa, A Ristimäki, ...
US Patent App. 17/058,926, 2021
2021
Screen for actionable ERBB3 mutations
MK Koivu, D Chakroborty, KJ Kurppa, K Elenius
Cancer Research 81 (13_Supplement), 2424-2424, 2021
2021
An unbiased in vivo screen for activating EGFR mutations
D Chakroborty, KJ Kurppa, K Elenius
Cancer Research 81 (13_Supplement), 2299-2299, 2021
2021
Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib
P Suominen, D Chakroborty, KJ Kurppa, I Diala, LD Eli, AS Lalani, ...
Cancer Research 81 (13_Supplement), 2420-2420, 2021
2021
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line
MKA Koivu, D Chakroborty, MZ Tamirat, MS Johnson, KJ Kurppa, ...
Databases, 2020
2020
iSCREAM-an unbiased pipeline to screen for activating kinase mutations
D Chakroborty, KJ Kurppa, I Paatero, LL Elo, K Elenius
Cancer Research 79 (13_Supplement), 1780-1780, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20